OXiGENE Reports Year-End 2008 Cash, Cash Equivalents and Marketable Securities Balance and Provides Corporate Update and Outlook for 2009
February 26, 2009 16:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., Feb. 26, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
OXiGENE to Present At BIO CEO and Investor Conference On February 9, 2009
February 02, 2009 16:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., Feb. 2, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye...
Drug Development Experts Nicole Onetto, M.D., and Eric Rowinsky, M.D. Join Symphony ViDA Board of Directors
January 12, 2009 02:19 ET
|
Oxigene, Inc.
Combined Experience Includes Integral Involvement in Development of Multiple
Blockbuster Oncology Products, Including Erbitux(r), Tarceva(r) and Taxol(r)
WALTHAM, Mass., Jan. 12, 2009 (GLOBE...
OXiGENE Stockholders Approve Share Issuance to Symphony Capital
December 09, 2008 16:05 ET
|
Oxigene, Inc.
Company to Receive $12.5 Million Equity Investment
WALTHAM, Mass., Dec. 9, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing...
OXiGENE Receives NASDAQ Notification
November 14, 2008 16:00 ET
|
Oxigene, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
medwards@oxigene.com
415-315-9413
OXiGENE Receives NASDAQ Notification
WALTHAM, Mass. -- November 14, 2008 -- OXiGENE, Inc....
OXiGENE to Present at Rodman and Renshaw, Lazard Healthcare Conferences
November 06, 2008 02:04 ET
|
Oxigene, Inc.
OXiGENE to Present at Rodman and Renshaw, Lazard Healthcare Conferences
WALTHAM, Mass., Nov. 6, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical...
OXiGENE Updates Progress and Reports Third Quarter 2008
November 05, 2008 02:25 ET
|
Oxigene, Inc.
OXiGENE Updates Progress and Reports Third Quarter 2008 Financial Results Body:
WALTHAM, Mass., Nov. 5, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical-stage,...
OXiGENE Announces Third Quarter 2008 Earnings Conference Call and Webcast
October 30, 2008 02:17 ET
|
Oxigene, Inc.
OXiGENE Announces Third Quarter 2008 Earnings Conference Call and Webcast
WALTHAM, MA - October 30, 2008 -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a
clinical-stage, biopharmaceutical company...
OXiGENE Reports Positive Phase 2 Interim Results in Platinum-Resistant Ovarian Cancer for Lead Vascular Disrupting Agent, ZYBRESTAT™
October 27, 2008 02:33 ET
|
Oxigene, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
medwards@oxigene.com ...
OXiGENE, Inc. Names John A. Kollins as Chief Executive Officer
October 23, 2008 02:00 ET
|
Oxigene, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
medwards@oxigene.com ...